Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).
Trial Details
- NCT ID
- NCT07149363
- Phase
- PHASE2
- Sponsor
- Alliance Foundation Trials, LLC.
- Status
- RECRUITING
- Cancer Type
- Lung Cancer
- Interventions
- Locations (sample)
- Chicago, Illinois, United States|41.85003,-87.65005
- Scarborough, Maine, United States|43.57814,-70.32172
- Boston, Massachusetts, United States|42.35843,-71.05977
- Boston, Massachusetts, United States|42.35843,-71.05977
- St Louis, Missouri, United States|38.62727,-90.19789
Key Eligibility Criteria
- Age ≥ 18 years.
- Body weight \>30 kg.
- Must have a life expectancy of at least 12 weeks.
- Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee o…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lung Cancer Trials on Trialify →